Results suggest a significantly higher PD-L1 gene expression in responding TMZ-treated tumours in comparison with control tumours (p < 0.0001), with a 1.07 ± 0.34 relative expression found for TMZ-treated tumours and a 0.46 ± 0.16 relative expression for control tumours (see Figure 4A for visual comparison). The gene discussed is CD274; the disease is neoplasm.